Award
National Cancer Institute 3UM1CA186712-09S1
The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network
Recipient
The Ohio State University
Award Amount
$1,697,412.00
Ceiling
$1,697,412.00
Awarded
June 01, 2026
Identifier
3UM1CA186712-09S1
Award to The Ohio State University as Lead Academic Organization for the Experimental Therapeutics Clinical Trials Network, funded by the National Cancer Institute for cancer therapy clinical trials and investigator training, with an award amount of $1,697,412.
Description
The project involves a multi-disciplinary team of basic scientists and clinical investigators focused on finding effective new therapies for cancer patients. It aims to enroll over 100 patients per year in ETCTN studies, with 136 enrollments recorded in the reporting period. The project emphasizes education and training of early career investigators. It is funded by the National Cancer Institute under grant number 3UM1CA186712-09S1, with a duration from March 1, 2026, to February 28, 2027. The project involves clinical trials related to advanced malignant neoplasms, immunotherapy, targeted therapies, and genomic profiling, located at Ohio State University, Columbus, Ohio.